Grow your own heart valve: first human trial launches
NCT ID NCT05809856
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new type of heart valve made from a patient's own tissue to treat a leaky pulmonary valve. Seven adults will receive the valve to see if it is safe and works well in the short term. The valve is designed to grow with the patient, potentially reducing the need for repeat surgeries.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 7 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2023
- Expected to finish
-
Dec 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age ≥ 18 years 2. Sufficient appropriate tissue (preferably: Pericardium for pericardiectomy via thoracoscopy or thoracotomy, or sternotomy; other options are fascia lata, rectus fascia, peritoneum or diaphragm) 3. Any of the following by transthoracic echocardiography and/or Cardiac Magnet Resonance Imaging: * For patients in New York Heart Association (NYHA) Classification II, III, or IV: Moderate (3+) or severe (4+) pulmonary regurgitation AND/OR mean systolic gradient across PV or RVOT ≥ 35 mmHg * For patients in NYHA Classification I: Severe (4+) pulmonary regurgitation with RV dilatation or dysfunction and/or mean PV or RVOT systolic gradient ≥ 40 mmHg * Right ventricular ejection fraction (RV-EF): \<40%. * Right ventricular end-diastolic volume (RVEDV): \>150 ml/m2 (body surface area) 4. Written informed consent provided by study subjects obtained before any research-related test is performed Exclusion Criteria: * Active endocarditis or myocarditis or within 3 months before the screening date * Patients unwilling or unable to provide written informed consent or comply with follow-up requirements * Obstruction of the central veins (including the superior and inferior vena cava, and bilateral iliac veins) such that the Ensemble-delivery system/ Performer™ - Guiding Sheath/ Extra Large Check-Flo® or GORE® DrySeal Flex + Ballon-in-Ballon-catheter cannot be advanced to the heart via a transvenous approach from either femoral vein or internal jugular * Requires emergency surgery * Recipient of transplanted organs or currently an organ transplant candidate * Pulmonary hypertension * Connective tissue disorders * Coronary artery disease * Immunosuppressive disease * Estimated survival of less than 6 months * Fertile females unable to take adequate contraceptive precautions (PEARL- Index \< 1%) * Females who are pregnant, or are currently breastfeeding an infant * Acute myocardial infarction within 30 days of the screening date * Stroke confirmed by CT, cerebrovascular accident (CVA), or transient ischemic attack (TIA) within 6 months before the screening date * Hemodynamic or respiratory instability requiring inotropic or/and mechanical circulatory support, or mechanical ventilation within 30 days before the screening date * Severe left ventricular systolic dysfunction with ejection fraction ≤ 20% or evidence of an intra-cardiac mass, thrombus, or vegetation assessed by echocardiography before the screening date * Renal insufficiency with creatinine level 2.5 mg/dl within 60 days before the screening date * Leukopenia with WBC \<3.5 x 109/L anemia with Hgb \<10 g/dl, or thrombocytopenia with platelet count \<50x103/l accompanied by a history of bleeding diathesis or coagulopathy within 60 days before the screening date * Adult subject is an illicit drug user, alcohol abuser, or unable to give informed consent * Subject is institutionalized by court order or by order of authority (e.g. prisoner, untreated psychiatry; limited compliance) * Major or progressive non-cardiac disease (liver failure, renal failure, cancer)that has a life expectancy of less than six months Inability to comply with all of the study procedures and follow-up visits * Subjects who are dependent on the sponsor or investigators
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pulmonary valve insufficiency are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Deutsches Herzzentrum der Charité
RECRUITINGBerlin, State of Berlin, 13353, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New heart valve trial offers hope for patients with rare congenital defects
- New heart valve device offers hope for patients with congenital defects
- New heart valve could spare congenital patients from repeat surgeries
- New heart valve system offers hope for patients with leaky pulmonary valves
- New heart valve passes safety check in 57 patients